All articles tagged with #coherus biosciences
The FDA has approved toripalimab, a PD-1 inhibitor developed by Junshi Biosciences, for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC) in the US market. Coherus BioSciences holds the rights for the drug in the US and Canada and plans to launch it under the brand name Loqtorzi in the first quarter of 2024.
Coherus BioSciences and Junshi Biosciences have announced that the U.S. Food and Drug Administration (FDA) has approved LOQTORZI™ (toripalimab-tpzi) for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC). LOQTORZI is the first and only FDA-approved treatment for NPC and can be used in combination with chemotherapy for first-line treatment or as monotherapy for patients with disease progression on or after platinum-containing chemotherapy, regardless of PD-L1 status. The approval was based on positive results from Phase 2 and Phase 3 studies, which showed significant improvements in progression-free survival and overall survival. LOQTORZI is a next-generation PD-1 monoclonal antibody that activates the immune system to kill tumors.
Coherus BioSciences has agreed to acquire Surface Oncology, a clinical-stage immuno-oncology company, for $40 million plus Surface's net cash. The acquisition adds two clinical stage assets to Coherus' I-O pipeline. The transaction is expected to close in Q3 of 2023.
Coherus BioSciences plans to sell a biosimilar version of Humira at an 85% discount from AbbVie's price, and will work with Mark Cuban's generic drug company to make the medicine available directly to consumers for even less. The move has the potential to alter one of the most closely watched product rollouts by pharmaceutical companies in many years, as AbbVie is expected to face at least eight biosimilar rivals to Humira by the end of the year.